A Research Study to Bank Samples for Future Evaluation to Identify Biomarkers That Predispose Crohn's Disease and Ulcerative Colitis Patients to Develop Hepatosplenic T-Cell Lymphoma (HSTCL)
N/A
N/A
Both
Hepatosplenic T-Cell Lymphoma
Trial Information
A Research Study to Bank Samples for Future Evaluation to Identify Biomarkers That Predispose Crohn's Disease and Ulcerative Colitis Patients to Develop Hepatosplenic T-Cell Lymphoma (HSTCL)
Inclusion Criteria:
- Patients with Inflammatory Bowel Disease with a confirmed diagnosis of Hepatosplenic
T-cell Lymphoma
Type of Study:
Interventional
Study Design:
Intervention Model: Single Group Assignment, Masking: Open Label
Outcome Measure:
Collection of samples to identify biomarkers
Outcome Description:
The objective of this study is to collect samples from IBD patients diagnosed with HSTCL for the purpose of identifying biomarkers that may allow either earlier evaluation of a patient's risk of developing HSTCL or possibly earlier diagnosis.
Outcome Time Frame:
Single timepoint of collection. Qualified subjects will be asked to provide samples at one time point (Day 1) during one visit with their study doctor.
Safety Issue:
No
Principal Investigator
Sujana Yerram, MD
Investigator Role:
Study Director
Investigator Affiliation:
Janssen Services
Authority:
United States: Food and Drug Administration
Study ID:
CR100938
NCT ID:
NCT01804166
Start Date:
January 2013
Completion Date:
October 2018
Related Keywords:
- Hepatosplenic T-cell Lymphoma
- Lymphoma, T-Cell, Peripheral
- Colitis
- Colitis, Ulcerative
- Crohn Disease
- Lymphoma
- Lymphoma, T-Cell
Name | Location |
|---|---|
| McLean, Virginia 22101 |
